Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Corcept Therapeutics Announces Presentations of Results of
Corcept Therapeutics (NASDAQ:CORT) Given New $100.00 Price Target at ...
Pipeline and Clinical Trials - Corcept Therapeutics
Therapeutic Areas - Corcept Therapeutics
Why Did Corcept Therapeutics Stock Surge Over 14% Today?
Products - Corcept Therapeutics
Corcept gets FDA OK for first-in-class ovarian cancer drug | pharmaphorum
Corcept Therapeutics Reports the US FDA’s NDA Acceptance of ...
Corcept Therapeutics logo in transparent PNG and vectorized SVG formats
Corcept (CORT) Advances Ovarian Cancer Therapy with FDA Filing for ...
Corcept Therapeutics Offices - Redwood City | Office Snapshots
Corcept Leadership & Board of Directors
Publications - Corcept Therapeutics
Contact Corcept Therapeutics | Inquiries & Support
Corcept Therapeutics: Buy Rating Backed by Promising Developments in ...
Corcept Therapeutics Gains FDA Approval for Relacorilant in New Drug ...
Corcept Therapeutics
Corcept Therapeutics shares double on solid Phase 3 results for ovarian ...
Founding Corcept - Corcept Therapeutics
Corcept Therapeutics (CORT) Announces Pivotal Data from Phase 3 ROSELLA ...
Corcept Therapeutics’ Miricorilant Study: A Potential Game-Changer for ...
Corcept tanks on FDA's CRL to relacorilant NDA in hypercortisolism
Corcept Therapeutics' Shares Boosted by FDA Approval of Ovarian Cancer ...
Corcept Therapeutics · GitHub
Stories - Corcept Therapeutics
Cushing’s Syndrome: A Patient Advocate Perspective - Corcept Therapeutics
Cortisol Modulation - Corcept Therapeutics
Corcept Therapeutics: A Breakthrough in Rare Diseases and Beyond
About - Corcept Therapeutics
Corcept Announces Positive Results in Treatment Phase of CATALYST Trial ...
Corcept Therapeutics receives FDA CRL for relacorilant NDA | CORT Stock ...
Job Openings - Corcept Therapeutics
Corcept Cares and SPARK - Korlym® (mifepristone) HCP
IR - Template - Corcept Therapeutics
Corcept Therapeutics submits FDA application for relacorilant to treat
Corcept Therapeutics Receives US FDA Approval for Ovarian Cancer Drug ...
Corcept Therapeutics to Report Q1 Earnings: What's in the Cards?
Corcept Therapeutics Receives FDA Complete Response Letter for ...
Corcept Therapeutics Patent Portfolio – Exemplary Landscape Overview ...
Corcept Therapeutics (CORT) Stock Rockets 40% as FDA Greenlights ...
Corcept Therapeutics legt nach FDA-Zulassung von Lifyorli zu: ROSELLA
Corcept Therapeutics (CORT): A Deep Dive into the 43.7% Earnings Growth ...
Corcept Gains FDA Approval In Ovarian Cancer (Rating Upgrade) (NASDAQ ...
Corcept Therapeutics Stock (CORT) Rockets Up 100% After Groundbreaking ...
Corcept Therapeutics Phase 3 ROSELLA Trial Achieves Survival Benefit ...
Corcept Therapeutics office design | Office Snapshots
Corcept Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Corcept Therapeutics Incorporated Stock — CORT Overview — Roic AI
Corcept Therapeutics (CORT) Company Profile, History, Products & Services
Corcept (CORT) Shares Rise 20% in Three Months: Here's Why
Corcept Therapeutics: Drug Discovery Collaboration
Corcept (CORT) Thrives on Korlym, Overdependence a Concern
Corcept Therapeutics Faces Major Setback with FDA Response - Investors ...
Corcept Therapeutics: A Stock on the Rise, But Is It a Buy? - Raging Bull
El fármaco oncológico de Corcept reduce un 35% el riesgo de muerte en ...
About Corcept Cares | Korlym® (mifepristone) 300 mg Tablets
Corcept Therapeutics' Relacorilant NDA Submission: A Breakthrough in ...
Corcept granted FDA nod for cancer therapy
Corcept Therapeutics Patent Portfolio: A Landscape Overview
Why Corcept Therapeutics Zoomed Nearly 9% Higher This Week
Corcept Therapeutics Shares Plunge 50% Following FDA Rejection of ...
Corcept says ROSELLA trial hit key endpoint for relacorilant combo ...
Corcept Therapeutics Stock Surges Amid Clinical Trial News - TipRanks.com
Corcept Pharmaceutical company.
Corcept Therapeutics shares surge as lead drug gets FDA nod for ovarian ...
Corcept Therapeutics Q2 2025 Earnings Preview
FDA Rejects Corcept Therapeutics' Drug for Rare Hormonal Disorder ...
Why Corcept Therapeutics Shares Climbed 10.8% Today | The Motley Fool
Corcept Therapeutics' Dazucorilant ALS Trial: A Survival Breakthrough ...
William Guyer - Corcept Therapeutics
Corcept Therapeutics Soars 14.5% on Landmark Ovarian Cancer Trial ...
Corcept Therapeutics Inc (NASDAQ:CORT): A GARP Pick with Accelerating ...
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial ...
Corcept Therapeutics: Despite FDA Blind Side, Relacorilant Remains A ...
Patient Portrait for Corcept Therapeutics — Steve Boxall Photography
FinancialContent - The Second Act: A Deep-Dive into Corcept ...
Corcept: The Cortisol Modulation Company | Corcept Therapeutics
Corcept Therapeutics' Regulatory Risk/Reward Profile: Navigating Mixed ...
Corcept Therapeutics (CORT) Rallies 0.90% on Nine-Day Surge, Clinical ...
Corcept Announces Positive Results From Open-Label Portion
Corcept's Relacorilant Efficacy in Cushing's Syndrome Study | Corcept ...
Corcept Therapeutics Submits NDA for Relacorilant to FDA for Cushing’s ...
Corcept Therapeutics Incorporated (CORT): Why Should You Buy This ...
Corcept Shows PFS Benefit: HR 0.60 in PARPi‑Treated Ovarian Cancer ...
Corcept (CORT) Rides High on Cushing's Syndrome Drug Korlym
UBS initiates coverage of Corcept Therapeutics (CORT) with neutral ...
Fármaco de Corcept contra cáncer de ovario reduce progresión de la ...
Corcept Therapeutics Stock Plummets 50% After FDA Request for More Data ...
Corcept向FDA提交Relacorilant治疗皮质醇增多症上市申请——药研快讯
FDA Files Corcept’s New Drug Application for Relacorilant as Treatment ...
Ovarian cancer data restores faith in Corcept's relacorilant | pharmaphorum
Corcept's ovarian cancer treatment under FDA review
Today, the FDA approved a new treatment option for patients with ...
FDA Accepts Corcept's Relacorilant NDA for Ovarian Cancer Treatment ...
Corcept’s Relacorilant Combo Approved for Resistant Ovarian Cancer ...
Corcept卵巢癌药物Lifyorli获FDA批准
Corcept's Breakthrough in Platinum-Resistant Ovarian Cancer Treatment ...
Corcept's ovarian cancer drug nabs FDA approval ahead of schedule
Corcept’s Relacorilant Shines in Ovarian Cancer Trial: A New Standard ...
Corcept: Korlym Defies Generics As Relacorilant Hits An FDA CRL (NASDAQ ...
FDA files Corcept’s NDA for Relacorilant as treatment in ...
